Propanc Biopharma (PPCB) Financials
Newest figures come from the S-1 for FY2026, filed Oct 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PPCB SEC filings page.
This page shows Propanc Biopharma, Inc. (PPCB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Propanc remains a development-stage business: larger research spending is funded mainly through financing while losses still consume operating cash.
In FY2026, the net loss was$18.9M , while operating cash outflow was$5.7M ; the gap means accounting losses were not a one-for-one cash drain. Financing cash flow of$6.5M slightly exceeded that outflow, showing the business relied on external funding to offset operations rather than internally generated cash.
Research and development rose
The current ratio rose from 1.5x in FY2025 to 2.5x in FY2026, indicating more current assets relative to near-term obligations. The reported liquidity comparison was 1.8 months of the latest annual operating outflow, so balance-sheet improvement did not eliminate dependence on financing.
Financial Health Signals
Propanc Biopharma, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Propanc Biopharma, Inc. passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.
Propanc Biopharma, Inc. reported a net loss of $18.9M while operations used $5.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Propanc Biopharma, Inc. reported an operating loss of $18.2M against $431K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2026.
Cash & Balance Sheet
Propanc Biopharma, Inc. recorded an outflow of $1.6M in free cash flow in Q4 2026, representing a cash shortfall after capex. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Propanc Biopharma, Inc. held $832K in cash as of Q4 2026; no long-term debt figure is on record for that period.
Not reported for Q4 2026.
Margins & Returns
None of these metrics is reported for Q4 2026.
Capital Allocation
Propanc Biopharma, Inc. invested $21 in capex in Q4 2026, funding long-term assets and infrastructure. Against the prior quarter it is down 86.4%.
Not reported for Q4 2026.
Not reported for Q4 2026.
PPCB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'26S-1 | Q3'26S-1 | Q2'26S-1 | Q1'26S-1 | Q4'25S-1 | Q3'25S-1 | Q2'25S-1 | Q1'25S-1 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $170K+213.6% | $20K-63.3% | $60K-2.5% | N/A | $54K-17.3% | $54K-52.3% | $62K+280.0% |
| SG&A Expenses | N/A | $6.2M-88.3% | $3.6M+2262.2% | $4.6M+1983.1% | N/A | $53.1M | $154K-51.7% | $221K-43.9% |
| Operating Income | N/A | -$6.4Mn/m | -$3.7Mn/m | -$4.7Mn/m | N/A | -$53.1M | -$213Kn/m | -$291Kn/m |
| EBITDA | N/A | -$6.4Mn/m | -$3.7M | -$4.7M | N/A | -$53.1M | N/A | N/A |
| Interest Expense | N/A | $38K-63.2% | $59K-50.4% | $306K+254.5% | N/A | $104K-21.9% | $119K-55.0% | $86K-51.6% |
| Net Income | N/A | -$6.4Mn/m | -$3.1M | -$4.8M | N/A | -$54.1M | N/A | N/A |
| EPS (Basic) | N/A | -$7.09 | -$0.30 | -$0.39 | N/A | -$312.46 | -$32.23 | -$35.97 |
| EPS (Diluted) | N/A | -$7.09 | -$0.30 | -$0.39 | N/A | -$312.46 | -$32.23 | -$35.97 |
| Diluted Shares (Avg) | N/A | 897,099 | 13M | 12M | N/A | 173,040 | 13,347 | 9,849 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
PPCB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'26S-1 | Q3'26S-1 | Q2'26S-1 | Q1'26S-1 | Q4'25S-1 | Q3'25S-1 | Q2'25S-1 | Q1'25S-1 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.8M-34.9% | $14.3M-36.4% | $15.1M+19142.3% | $18.0M+28144.1% | $19.6M+27028.9% | $22.5M+60235.2% | $79K-67.5% | $64K-64.7% |
| Current Assets | $8.5M+2.3% | $8.2M-15.5% | $7.7M+42754.3% | $8.8M+40596.0% | $8.4M+32732.1% | $9.7M+75637.5% | $18K-91.5% | $22K-85.2% |
| Cash & Equivalents | $832K+6782.9% | $444K+774.1% | $561K+3735.4% | $603K+6403.4% | $12K-42.7% | $51K+715.8% | $15K-79.6% | $9K+39.9% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $3.4M-41.0% | $3.5M-21.0% | $3.7M-13.6% | $3.6M-13.4% | $5.7M+48.7% | $4.4M+18.7% | $4.2M+11.3% | $4.2M+31.6% |
| Current Liabilities | $3.4M-39.9% | $3.5M-19.9% | $3.6M-12.8% | $3.6M-12.9% | $5.6M+47.1% | $4.3M+17.7% | $4.2M+10.4% | $4.1M+30.9% |
| Non-Current Liabilities | $24K-83.8% | $30K-67.8% | $35K-57.2% | $42K-40.3% | $147K+151.3% | $94K+92.2% | $82K+90.3% | $70K+93.0% |
| Long-Term Debt | N/A | $55K-87.5% | $55K-86.6% | $107K-72.0% | $538K+34.7% | $439K-24.8% | $410K-40.4% | $382K-3.9% |
| Total Equity | $9.4M-32.4% | $9.8M-45.7% | $10.5Mn/m | $14.4Mn/m | $13.9Mn/m | $18.1Mn/m | -$4.2Mn/m | -$4.1Mn/m |
| Retained Earnings | -$144.5Mn/m | -$140.8Mn/m | -$134.5Mn/m | -$130.5Mn/m | -$125.6Mn/m | -$121.6Mn/m | -$67.5Mn/m | -$67.1Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
PPCB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'26S-1 | Q3'26S-1 | Q2'26S-1 | Q1'26S-1 | Q4'25S-1 | Q3'25S-1 | Q2'25S-1 | Q1'25S-1 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.6Mn/m | -$1.1Mn/m | -$999K-5434.7% | -$1.9Mn/m | -$92Kn/m | -$96Kn/m | $19Kn/m | -$236Kn/m |
| Depreciation & Amortization | $327 | $316n/m | $229 | $125 | N/A | $0-100.0% | N/A | N/A |
| Stock-Based Compensation | N/A | $5.4M-89.9% | $1.8M | $3.0M | N/A | $52.8M | N/A | N/A |
| Capital Expenditures | $21 | $154 | $2K | $2K | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$1.6M | -$1.1M | -$1.0M | -$1.9M | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$21 | -$154 | -$2K | -$2K | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $2.0M+2626.7% | $982K+565.6% | $965K+1660.6% | $2.5M+1071.4% | $73K-71.0% | $147K+121.3% | $55K-80.0% | $216K-38.4% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PPCB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'26S-1 | Q3'26S-1 | Q2'26S-1 | Q1'26S-1 | Q4'25S-1 | Q3'25S-1 | Q2'25S-1 | Q1'25S-1 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | -64.7%+234.1pp | -29.6% | -33.7% | N/A | -298.8% | N/A | N/A |
| Return on Assets | N/A | -44.4%+195.6pp | -20.5% | -26.9% | N/A | -240.0% | N/A | N/A |
| Current Ratio | 2.55+1.0x | 2.37+0.1x | 2.13+2.1x | 2.45+2.4x | 1.50+1.5x | 2.24+2.2x | 0.00-0.1x | 0.010.0x |
| Debt-to-Equity | N/A | 0.010.0x | 0.01 | 0.01 | 0.04 | 0.02 | N/A | N/A |
| Liabilities-to-Equity | 0.36-0.1x | 0.36+0.1x | 0.35 | 0.25 | 0.41 | 0.25 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Propanc Biopharma, Inc. PPCB | FY2026 | N/A | -$18.9M | N/A | N/A | — |
| Akari Therapeutics plc AKTX | FY2025 | N/A | -$17.3M | N/A | $19.6M | — |
| Allarity Therapeutics, Inc. ALLR | FY2025 | $320K | -$11.2M | N/A | $14.6M | — |
| Boundless Bio, Inc. BOLD | FY2025 | N/A | -$58.2M | N/A | $55.7M | — |
| Rein Therapeutics, Inc. RNTX | FY2025 | $0 | -$49.9M | N/A | $60.7M | — |
Where Propanc Biopharma, Inc. Ranks
Frequently Asked Questions
Is Propanc Biopharma, Inc. profitable?
No, Propanc Biopharma, Inc. (PPCB) reported a net loss of $18.9M in fiscal year 2026.
What is Propanc Biopharma, Inc.'s EBITDA?
Propanc Biopharma, Inc. (PPCB) had EBITDA of -$18.2M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Propanc Biopharma, Inc.'s return on equity (ROE)?
Propanc Biopharma, Inc. (PPCB) has a return on equity of -200.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Propanc Biopharma, Inc.'s free cash flow?
Propanc Biopharma, Inc. (PPCB) recorded an outflow of $5.7M in free cash flow during fiscal year 2026. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Propanc Biopharma, Inc.'s operating cash flow?
Propanc Biopharma, Inc. (PPCB) recorded an outflow of $5.7M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Propanc Biopharma, Inc.'s total assets?
Propanc Biopharma, Inc. (PPCB) had $12.8M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Propanc Biopharma, Inc.'s capital expenditures?
Propanc Biopharma, Inc. (PPCB) invested $5K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Propanc Biopharma, Inc. spend on research and development?
Propanc Biopharma, Inc. (PPCB) invested $625K in research and development during fiscal year 2026.
What is Propanc Biopharma, Inc.'s current ratio?
Propanc Biopharma, Inc. (PPCB) had a current ratio of 2.55 as of fiscal year 2026, which is generally considered healthy.
What is Propanc Biopharma, Inc.'s liabilities-to-equity ratio?
Propanc Biopharma, Inc. (PPCB) had a liabilities-to-equity ratio of 0.36 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.
What is Propanc Biopharma, Inc.'s return on assets (ROA)?
Propanc Biopharma, Inc. (PPCB) had a return on assets of -147.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
How does Propanc Biopharma, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Propanc Biopharma, Inc. (PPCB) held $832K in cash, cash equivalents and investments, and reported an operating cash outflow of $5.7M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Propanc Biopharma, Inc.'s Piotroski F-Score?
Propanc Biopharma, Inc. (PPCB) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Propanc Biopharma, Inc.'s earnings high quality?
Propanc Biopharma, Inc. (PPCB) reported a net loss of $18.9M while operations used $5.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Propanc Biopharma, Inc. cover its interest payments?
Propanc Biopharma, Inc. (PPCB) reported an operating loss of $18.2M against $431K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.